Glutathione-S-transferase P1 (GSTP1) is involved in thiol-mediated detoxification and breakdown of reactive oxygen species created by anticancer drug exposure. GSTP1 is also an inhibitor of c-Jun N-terminal kinase 1, a kinase involved in stress response, apoptosis and cellular proliferation. Hypermethylation of the *GSTP1*promoter has been associated with gene silencing in prostate cancer, kidney cancer, and breast cancer, among others. Although frequently described, the mechanism underlying promoter hypermethylation of the *GSTP1*gene is poorly understood. It has been reported that an ATAAA repeat of the *GSTP1*promoter separates methylated from unmethylated CpGs in normal prostate tissue \[[@B1]\]. These separate methylation domains are lost in prostate cancer, and methylation extends throughout the whole promoter region. It has been proposed that hypermethylation of *GSTP1*requires a combination of gene silencing and random seeds of methylation in prostate cancer cells, and that these combinatorial effects lead to histone deacetylation and subsequent chromatin remodeling \[[@B2]\]. To further elucidate the mechanisms underlying the hypermethylation of the *GSTP1*promoter, we genotyped the (ATAAA) repeat and the linked SNPs in positions -354, -288, -287 and -282 in the *GSTP1*promoter and we performed methylation analysis using mass spectrometry in tumor DNA from 82 breast cancer patients. The role of the different allelic variants on methylation status of the *GSTP1*promoter and expression levels was assessed. We quantitatively determined the methylation status of six CpGs spanning the transcription start site of the GSTP1 promoter: -22, +8, +14, +38, +47 and +55. The average percentage methylation for each individual CpG for the 82 tumor samples analyzed was 16.9%, 30.3%, 18.2%, 21.2%, 18.6% and 8.1%, respectively. The average percentage methylation for all CpGs in all tumor samples was 19%. There was a correlation between the degree of methylation of the individual CpGs and their neighboring CpGs (*P*\< 0.001). When correlating the extent of methylation to the mRNA levels previously assessed by whole genome gene-expression profiling of the same tumors, a significant inverse correlation was observed (*P*\< 0.01). The methylation status of the three CpGs closest to the transcriptional start site was more highly associated with the level of *GSTP1*mRNA expression than the CpGs further downstream of the +1 site. Furthermore, we observed differences in the degree of *GSTP1*promoter methylation between the different tumor subclasses defined by whole-genome microarray analysis \[[@B3]\]. The methylation of the *GSTP1*promoter was significantly lower in the basal subtype compared with the luminal subtype, which corresponded to elevated *GSTP1*mRNA levels in the basal subtypes \[[@B4]\]. We further analyzed the impact of the most frequent haplotype structure of the *GSTP1*promoter in relation to the extent of methylation, and a correlation was observed (*P*= 0.003) suggesting that haplotype structures can affect *de novo*methylation of adjacent sequences.
